This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koesters, R. Articles by Doeberitz, M. v. K. Search for Related Content PubMed PubMed Citation Articles by Koesters, R. Articles by Doeberitz, M. v. K.

Mutational Activation of the ß-Catenin Proto-Oncogene Is a Common Event in the Development of Wilms’ Tumors¹

Department of Surgery, University of Heidelberg, 69120 Heidelberg, Germany [R. K., R. R., M. v. K. D.]; Central Division of Biostatistics, Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany [A. K-S.]; Children’s Hospital of Zurich, 8032 Zurich, Switzerland [D. B., F. N.]; Heart Center, University of Leipzig, 04289 Leipzig, Germany [V. A.]; and Institute of Histological and Cytological Diagnostics, 5001 Aarau, Switzerland [J. B.]

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Activation of ß-catenin-mediated transcription is the nuclear end point of organ-specific Wnt signaling. In the developing kidney, Wnt-4, a secreted glycoprotein, acts as an autoinducer of the mesenchymal to epithelial transition that underlies normal nephron development. Dysregulation of this epithelial transformation process may lead to Wilms’ tumors (WTs). In this study, we investigated the potential role of the ß-catenin proto-oncogene, a candidate downstream target molecule of Wnt-4 signaling, in the development of WTs. In 6 of 40 tumors (15%), mutation analysis revealed heterozygous missense mutations or small deletions that result in the loss of important regulatory phosphorylation sites within the ß-catenin protein. These findings indicate that activating ß-catenin mutations may play a significant role in the development of WTs and establish a direct link between Wilms’ tumorigenesis and the Wnt signal transduction pathway governing normal kidney development.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
WT³ or nephroblastoma, an embryonic kidney-derived tumor, is one of the most common solid pediatric malignancies affecting about 1 in 10,000 children. Most WTs are sporadic and unilateral, whereas familial and bilateral tumors occur in only 1% and 7% of the cases, respectively. WTs have been proposed to fit a "two-hit" model of carcinogenesis (1) . According to this model, WTs are caused by two independent mutational hits. In sporadic cases, both hits occur as somatic mutations, whereas in inherited cases one mutation is already present in the germ line and only the second mutation is acquired somatically. This intriguingly simple two-hit model, however, has been complicated by the fact that the two hits required may affect the two alleles of several distinct WT suppressor genes. These have been mapped to chromosomes 11p13, 11p15, 16q, and 1p (2, 3, 4, 5, 6) . Thus far, only the WT1 gene, residing at 11p13, has been molecularly characterized (7 , 8) . This gene encodes a transcription factor that plays a pivotal role in the development of the kidney and also the gonads. Constitutional mutations of this gene lead to Denys-Drash syndrome, a triad of pseudohermaphroditism, glomerulopathy, and WT (9) . The WT1 gene has been found to be mutationally inactivated in a subset of WTs (10) .

ß-Catenin is involved in the developmental Wnt/wingless signal transduction pathway (11 , 12) . Oncogenic activation of this protein has been found to occur in several human cancers and is caused by mutations affecting a specific degradation targeting box near the NH₂ terminus of the ß-catenin protein (13, 14, 15, 16, 17) . In the developing kidney, Wnt-4 is required for the transition of metanephric blastema to renal epithelial cells (18) , and signaling is likely to occur via ß-catenin. Because WTs are the result of molecular alterations that lead to disturbance of this mesenchymal-to-epithelial transition, we considered the ß-catenin proto-oncogene a candidate gene to be involved in Wilms’ tumorigenesis.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Patient Samples.
Surgical resection specimens were obtained from 34 patients undergoing surgery for WT at the Kinderspital Zurich, Inselspital Bern, Kantonsspital Chur, and University Hospital of Geneva. After resection of the tumor, part of the material was immediately snap-frozen in liquid nitrogen and stored at -80°C. Formalin-fixed and paraffin-embedded samples of all tumors were examined by a pathologist at the University Hospital of Zurich.

DNA Preparation and PCR Amplification.
DNA was isolated from snap-frozen tissues, as described (19) . Exon 3 of ß-catenin was amplified by PCR using primers bcat-fwd1 (5'-GCTGATTTGATGGAGTTGGA-3') and bcat-rev1 (5'-GCTACTTGTTCTTGAGTGAA-3'). Reactions contained 2 mM MgCl₂ and 1 unit of TaKaRa Ex-Taq polymerase. Cycling conditions were: initial denaturation for 5 min at 94°C, 35 cycles of denaturation for 30 s at 94°C, 30-s annealing at 55°C, and 30-s elongation at 72°C, followed by a final elongation step for 7 min at 72°C.

DNA Sequencing.
PCR fragments were purified using High Pure PCR Purification kit (Roche Diagnostics), essentially as recommended by the manufacturer. For cloning, purified PCR fragments were ligated into the vector pCR 2.1 using the TA cloning system (Invitrogen). Plasmid DNA was purified by using High Pure Plasmid Isolation kit (Roche Diagnostics). Sequencing reactions were set up using either 30 ng of purified PCR fragment or 250 ng of plasmid DNA as template and 10 pmol of sequencing primer in a total reaction volume of 10 µl following a dye terminator protocol (Big Dye; Perkin-Elmer). The sequencing reactions were run on an ABI Prism 310 DNA Sequencer (Perkin-Elmer). Sequencing primers of ß-catenin exon 3 were bcat-fwd2 (5'-GGAGTTGGACATGGCCATGG-3') and bcat-rev2 (5'-CCTGTTCCCACTCATACAGG-3'). All mutations found were verified by sequencing both of the DNA strands and by analyzing a second, independently generated PCR amplicon.

Western Blot Analysis.
Snap-frozen tissue samples cut into 20-µm sections were used for total cellular protein extraction in lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mM sodium chloride, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.02% sodium azide, and 1 mM phenylmethylsulfonyl fluoride]. Aliquots of 100 µg of soluble protein were electrophoresed on 8% SDS-polyacrylamide gels, transferred to polyvinylidene difluoride membranes (Millipore), and probed with monoclonal antibodies specific for ß-catenin (1:1000 dilution; Transduction Laboratories) or ß-actin (1:1000; ICN). Horseradish peroxidase-conjugated rabbit antimouse IgG antiserum (Dianova) was used as secondary antibody. The membranes were developed using an enhanced chemiluminescence system (Amersham-Pharmacia).

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
To examine whether WTs bear mutations in ß-catenin, the conserved GSK-3ß phosphorylation consensus region encoding the regulatory degradation targeting box of ß-catenin was amplified by PCR, and the resulting PCR fragments were subjected to direct sequencing. By screening 41 WT specimens derived from 40 patients, we detected seven samples that displayed sequence ambiguities in their primary PCR products, indicating the presence of nonidentical alleles. On cloning, we identified in-frame deletions, as well as single nucleotide changes, that have occurred in these tumors (Table 1) . Tumors NT4, NT8, NT38, and S.M. were found to harbor a common deletion of codon 45 that causes loss of a functionally important serine phosphorylation site. It is of importance to note that NT4 and NT8 were local and metastatic recurrences of the same tumor (NT3), respectively, and, therefore, provided independent evidence for the distinct ß-catenin mutation found in this patient. Unfortunately, no material was available from the primary tumor in this case. Missense mutations within codon 45 were observed in NT21 and M.M. tumors and result in substitution of serine by cysteine or proline, respectively. One mutation was found in codon 41 (NT9) and replaces a threonine phosphorylation site by alanine. Representative examples of the mutational analysis are shown in Fig. 1 . Taking into account that tumors NT4 and NT8 both were recurrent tumors of the same patient (NT3), 6 independent tumors among a total number of 40 (15%) have been identified that contained mutations of ß-catenin (Fig. 2) . All mutations were found in a heterozygous state in the tumor, and no mutations were found in the normal kidney when available (NT21, NT38, S.M.). All of the affected tumors were of early stage and with no histopathological evidence for anaplastic progression (Table 1) . In two cases, a sporadic tumor (S.M.) and a Denys-Drash associated-tumor (NT21), ß-catenin mutations were found in tumors also known to harbor mutations in the WT1 gene (20 , 21) .

View larger version (36K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Nucleotide sequences of ß-catenin mutations in four WT specimens. Electropherograms for the regions comprising codon 41 (NT9) and codon 45 (M.M., NT21, and S.M.) showing wild-type (wt) sequences derived from control samples (top), sequences derived from direct sequencing of tumor (tu)-derived PCR fragments (middle), and sequences of isolated mutant alleles as obtained after subcloning (bottom). The affected codons are boxed, and the affected nucleotides are indicated by an arrow.

View larger version (15K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Schematic representation of the location of ß-catenin mutations in WTs. Boldface type, residues representing potential GSK-3ß phosphorylation sites at codons 33, 37, 41, and 45. Amino acid substitutions are indicated above. , deleted codon 45.

View larger version (41K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Western blot analysis of tumor (tu) and normal kidney (kid)-derived tissue lysates from patients NT21 and S.M. using monoclonal antibodies specific for ß-catenin and ß-actin. Both tumors bear a mutated ß-catenin gene.

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

Our findings indicate that ß-catenin mutations represent a common event in the development of WTs (15% in our patient group) and seem to occur more frequently than mutations of WT1 (10%) or p53 (5%; Refs. 10 and 25 ). The latter have been found only in the rare anaplastic variants of WTs. The ß-catenin mutations found in WTs in each case eliminated a functionally important GSK-3ß phosphorylation site at the NH₂ terminus of the ß-catenin protein. Such mutations have been shown to lead to stabilization of the ß-catenin protein and exert a dominant effect at the level of ß-catenin/TCF-mediated transcription (14) . Furthermore, the mutations found in WTs are identical to mutations that have been previously shown to occur in other human cancers (13, 14, 15, 16, 17) . Together, these data imply that ß-catenin mutations are causatively involved in the development of WTs.

Accumulating evidence suggests an important physiological role of the Wnt-signaling pathway during normal organ development. In the embryonic kidney, Wnt-4 is required for the mesenchymal-to-epithelial transition (18) . It is a fatal malfunctioning of the latter process that gives rise to WTs. These tumors derive from mesenchymal cells that normally should differentiate into the epithelial components of the nephron. Because ß-catenin is likely to be a downstream mediator of Wnt-4 signaling, the finding of activating mutations in the ß-catenin gene in WTs underlines the importance of the Wnt signal transduction pathway in the developing mammalian kidney.

Collecting more data on ß-catenin mutations and uncovering the identity of the remaining WT genes is required to clear up the complex picture of WT genetics. We are confident that the finding of ß-catenin mutations in WTs opens up new perspectives in research on WTs, as well as on normal kidney development.

	ACKNOWLEDGMENTS

 
We thank R. Moos, D. Koppenhoefer, and A. Siermann for technical assistance. The help provided by Dr. S. I. Peter is also gratefully acknowledged.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by the Krebsliga des Kantons Zürich and Schweizer Forschungsstiftung Kind und Krebs.

² To whom requests for reprints should be addressed, at Division of Molecular Diagnostics and Therapy, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. Phone: 49-6221-422467; Fax: 49-6221-422417; E-mail: R.Koesters{at}DKFZ-Heidelberg.de

³ The abbreviations used are: WT, Wilms’ tumor; GSK-3ß, glycogen synthetase kinase-3ß.

Received 4/28/99. Accepted 7/ 2/99.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. Knudson A. G., Jr., Strong L. C. Mutation and cancer: a model for Wilms’ tumor of the kidney. J. Natl. Cancer Inst., 48: 313-324, 1972.
2. van Heyningen V., et al Molecular analysis of chromosome 11 deletions in aniridia-Wilms’ tumor syndrome. Proc. Natl. Acad. Sci. USA, 82: 8592-8596, 1985.[Abstract/Free Full Text]
3. Mannens M., et al Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms’ tumors. Hum. Genet., 81: 41-48, 1988.[Medline]
4. Maw M. A., et al A third Wilms’ tumor locus on chromosome 16q. Cancer Res., 52: 3094-3098, 1992.[Abstract/Free Full Text]
5. Steenman M., et al Comparative genomic hybridization analysis of Wilms’ tumors. Cytogenet. Cell Genet., 77: 296-303, 1997.[Medline]
6. Grundy P. E., et al Loss of heterozygosity for chromosomes 16q and 1p in Wilms’ tumors predicts an adverse outcome. Cancer Res., 54: 2331-2333, 1994.[Abstract/Free Full Text]
7. Call K. M., et al Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell, 60: 509-520, 1990.[Medline]
8. Gessler M., et al Homozygous deletion in Wilms’ tumors of a zinc-finger gene identified by chromosome jumping. Nature (Lond.), 343: 774-778, 1990.[Medline]
9. Pelletier J., et al Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell, 67: 437-447, 1991.[Medline]
10. Varanasi R., et al Fine structure analysis of the WT1 gene in sporadic Wilms’ tumors. Proc. Natl. Acad. Sci. USA, 91: 3554-3558, 1994.[Abstract/Free Full Text]
11. Munemitsu S., Albert I., Rubinfeld B., Polakis P. Deletion of an amino-terminal sequence stabilizes ß-catenin in vivo and promotes hyperphosphorylation of the adenomatous polyposis coli tumor suppressor protein. Mol. Cell. Biol., 16: 4088-4096, 1996.[Abstract]
12. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. ß-catenin is a target for the ubiquitin-proteasome pathway. EMBO J., 16: 3797-3805, 1997.[Medline]
13. Robbins P. F., et al A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med., 183: 1185-1192, 1996.[Abstract/Free Full Text]
14. Morin P. J., et al Activation of ß-catenin/Tcf signaling in colon cancer by mutations in ß-catenin or APC. Science (Washington DC), 275: 1787-1790, 1997.[Abstract/Free Full Text]
15. Kitaeva M. N., et al Mutations in ß-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res., 57: 4478-4481, 1997.[Abstract/Free Full Text]
16. Sparks A. B., Morin P. J., Vogelstein B., Kinzler K. W. Mutational analysis of the APC/ß catenin/Tcf pathway in colorectal cancer. Cancer Res., 58: 1130-1134, 1998.[Abstract/Free Full Text]
17. Miyoshi Y., et al Activation of the ß-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res., 58: 2524-2527, 1998.[Abstract/Free Full Text]
18. Kispert A., Vainio S., McMahon A. P. Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. Development (Camb.), 125: 4225-4234, 1998.[Abstract]
19. Krieg P., Amtmann E., Sauer G. The simultaneous extraction of high-molecular-weight DNA and of RNA from solid tumors. Anal. Biochem., 134: 288-294, 1983.[Medline]
20. Koesters R., et al Mutational analysis of the tumor suppressor gene WT1: detection of a novel homozygous point mutation in sporadic unilateral Wilms’ tumor. Int. J. Oncol., 7: 1103-1107, 1995.
21. Stallmach T., Neuhaus T. J., Koesters R., Hailemariam S. Glomerulopathy in Denys-Drash syndrome. Case report of a model disease. Pathologe, 19: 230-234, 1998.[Medline]
22. Bullions L. C., Levine A. J. The role of ß-catenin in cell adhesion, signal transduction, and cancer. Curr. Opin. Oncol., 10: 81-87, 1998.[Medline]
23. He T. C., et al Identification of c-MYC as a target of the APC pathway. Science (Washington DC), 281: 1509-1512, 1998.[Abstract/Free Full Text]
24. Tetsu O., McCormick F. ß-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (Lond.), 398: 422-426, 1999.[Medline]
25. Bardeesy N., et al Anaplastic Wilms’ tumor, a subtype displaying poor prognosis, harbors p53 gene mutations. Nat. Genet., 7: 91-97, 1994.[Medline]

This article has been cited by other articles:

				H. Chang, F. Guillou, M. M. Taketo, and R. R. Behringer Overactive Beta-Catenin Signaling Causes Testicular Sertoli Cell Tumor Development in the Mouse Biol Reprod, November 1, 2009; 81(5): 842 - 849. [Abstract] [Full Text] [PDF]

				K. M. Cadigan and M. Peifer Wnt Signaling from Development to Disease: Insights from Model Systems Cold Spring Harb Perspect Biol, August 1, 2009; 1(2): a002881 - a002881. [Abstract] [Full Text] [PDF]

				M. K.-H. Kim, T. J. McGarry, P. O Broin, J. M. Flatow, A. A.-J. Golden, and J. D. Licht An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1 PNAS, July 7, 2009; 106(27): 11154 - 11159. [Abstract] [Full Text] [PDF]

				M. N. Rivera, W. J. Kim, J. Wells, A. Stone, A. Burger, E. J. Coffman, J. Zhang, and D. A. Haber The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity PNAS, May 19, 2009; 106(20): 8338 - 8343. [Abstract] [Full Text] [PDF]

				A. J. Chien, E. C. Moore, A. S. Lonsdorf, R. M. Kulikauskas, B. G. Rothberg, A. J. Berger, M. B. Major, S. T. Hwang, D. L. Rimm, and R. T. Moon Activated Wnt/ss-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model PNAS, January 27, 2009; 106(4): 1193 - 1198. [Abstract] [Full Text] [PDF]

				L. Miele, N. Takebe, and S. P. Ivy The Cancer Stem Cell Hypothesis, Embryonic Signaling Pathways, and Therapeutics: Targeting an Elusive Concept ASCO Educational Book, January 1, 2009; 2009(1): 145 - 156. [Abstract] [Full Text] [PDF]

				C. Owen, P. Virappane, M. Alikian, I. Stasevich, K. Summers, D. Lillington, D. Bonnet, A. Burnett, K. Mills, T. A. Lister, et al. WTX is rarely mutated in acute myeloid leukemia Haematologica, June 1, 2008; 93(6): 947 - 948. [Full Text] [PDF]

				C. Uschkereit, N. Perez, C. de Torres, M. Kuff, J. Mora, and B. Royer-Pokora Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation J. Med. Genet., June 1, 2007; 44(6): 393 - 396. [Abstract] [Full Text] [PDF]

				M. B. Major, N. D. Camp, J. D. Berndt, X. Yi, S. J. Goldenberg, C. Hubbert, T. L. Biechele, A.-C. Gingras, N. Zheng, M. J. MacCoss, et al. Wilms Tumor Suppressor WTX Negatively Regulates WNT/{beta}-Catenin Signaling Science, May 18, 2007; 316(5827): 1043 - 1046. [Abstract] [Full Text] [PDF]

				C.-N. Qian, J. Knol, P. Igarashi, F. Lin, U. Zylstra, B. T. Teh, and B. O. Williams Cystic Renal Neoplasia Following Conditional Inactivation of Apc in Mouse Renal Tubular Epithelium J. Biol. Chem., February 4, 2005; 280(5): 3938 - 3945. [Abstract] [Full Text] [PDF]

				A Ramburan, F Oladiran, C Smith, G P Hadley, and D Govender Microsatellite analysis of the adenomatous polyposis coli (APC) gene and immunoexpression of {beta} catenin in nephroblastoma: a study including 83 cases treated with preoperative chemotherapy J. Clin. Pathol., January 1, 2005; 58(1): 44 - 50. [Abstract] [Full Text] [PDF]

				C.-M. Li, C. E. Kim, A. A. Margolin, M. Guo, J. Zhu, J. M. Mason, T. W. Hensle, V. V.V.S. Murty, P. E. Grundy, E. R. Fearon, et al. CTNNB1 Mutations and Overexpression of Wnt/{beta}-Catenin Target Genes in WT1-Mutant Wilms' Tumors Am. J. Pathol., December 1, 2004; 165(6): 1943 - 1953. [Abstract] [Full Text] [PDF]

				G. Prindull and D. Zipori Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm Blood, April 15, 2004; 103(8): 2892 - 2899. [Abstract] [Full Text] [PDF]

				J Alami, B R Williams, and H Yeger Differential expression of E-cadherin and {beta} catenin in primary and metastatic Wilms's tumours Mol. Pathol., August 1, 2003; 56(4): 218 - 225. [Abstract] [Full Text] [PDF]

				R. Koesters, M. A. Hans, A. Benner, R. Prosst, J. Boehm, J. Gahlen, and M. von Knebel Doeberitz Predominant mutation of codon 41 of the {beta}-catenin proto-oncogene in rat colon tumors induced by 1,2-dimethylhydrazine using a complete carcinogenic protocol Carcinogenesis, November 1, 2001; 22(11): 1885 - 1890. [Abstract] [Full Text] [PDF]

				S. C. Abraham, T.-T. Wu, D. S. Klimstra, L. S. Finn, J.-H. Lee, C. J. Yeo, J. L. Cameron, and R. H. Hruban Distinctive Molecular Genetic Alterations in Sporadic and Familial Adenomatous Polyposis-Associated Pancreatoblastomas : Frequent Alterations in the APC/{beta}-Catenin Pathway and Chromosome 11p Am. J. Pathol., November 1, 2001; 159(5): 1619 - 1627. [Abstract] [Full Text] [PDF]

				E. Sadot, B. Geiger, M. Oren, and A. Ben-Ze'ev Down-Regulation of {beta}-Catenin by Activated p53 Mol. Cell. Biol., October 15, 2001; 21(20): 6768 - 6781. [Abstract] [Full Text] [PDF]

				W. Szeto, W. Jiang, D. A. Tice, B. Rubinfeld, P. G. Hollingshead, S. E. Fong, D. L. Dugger, T. Pham, D. G. Yansura, T. A. Wong, et al. Overexpression of the Retinoic Acid-responsive Gene Stra6 in Human Cancers and Its Synergistic Induction by Wnt-1 and Retinoic Acid Cancer Res., May 1, 2001; 61(10): 4197 - 4205. [Abstract] [Full Text]

				H. Takayasu, H. Horie, E. Hiyama, T. Matsunaga, Y. Hayashi, Y. Watanabe, S. Suita, M. Kaneko, F. Sasaki, K. Hashizume, et al. Frequent Deletions and Mutations of the {beta}-Catenin Gene Are Associated with Overexpression of Cyclin D1 and Fibronectin and Poorly Differentiated Histology in Childhood Hepatoblastoma Clin. Cancer Res., April 1, 2001; 7(4): 901 - 908. [Abstract] [Full Text]

				G. Garcia-Rostan, R. L. Camp, A. Herrero, M. L. Carcangiu, D. L. Rimm, and G. Tallini {beta}-Catenin Dysregulation in Thyroid Neoplasms : Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis Am. J. Pathol., March 1, 2001; 158(3): 987 - 996. [Abstract] [Full Text] [PDF]

				S. C. Abraham, E. A. Montgomery, F. M. Giardiello, and T.-T. Wu Frequent {beta}-Catenin Mutations in Juvenile Nasopharyngeal Angiofibromas Am. J. Pathol., March 1, 2001; 158(3): 1073 - 1078. [Abstract] [Full Text] [PDF]

				S. Maiti, R. Alam, C. I. Amos, and V. Huff Frequent Association of {beta}-Catenin and WT1 Mutations in Wilms Tumors Cancer Res., November 1, 2000; 60(22): 6288 - 6292. [Abstract] [Full Text]

				P. Polakis Wnt signaling and cancer Genes & Dev., August 1, 2000; 14(15): 1837 - 1851. [Full Text]

				S. Hosono, I. Gross, M. A. English, K. M. Hajra, E. R. Fearon, and J. D. Licht E-cadherin Is a WT1 Target Gene J. Biol. Chem., April 6, 2000; 275(15): 10943 - 10953. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koesters, R. Articles by Doeberitz, M. v. K. Search for Related Content PubMed PubMed Citation Articles by Koesters, R. Articles by Doeberitz, M. v. K.